Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations

• Published in: Brain (London, England : 1878) Vol. 137; no. Pt 12; pp. 3160 - 3170
• Main Authors: BÖHM, Johann, BIANCALANA, Valérie, LAFORET, Pascal, MAISONOBE, Thierry, OLIVE, Montse, GONZALEZ-MERA, Laura, FARDEAU, Michel, CARRIERE, Nathalie, CLAVELOU, Pierre, EYMARD, Bruno, BITOUN, Marc, RENDU, John, MALFATTI, Edoardo, FAURE, Julien, WEIS, Joachim, MANDEL, Jean-Louis, ROMERO, Norma B, LAPORTE, Jocelyn, DONDAINE, Nicolas, KOCH, Catherine, VASLI, Nasim, KRESS, Wolfram, STRITTMATTER, Matthias, TARATUTO, Ana Lia, GONORAZKY, Hernan
• Format: Journal Article
• Language: English
• Published: Oxford Oxford University Press 01-12-2014
• Subjects: Adaptor Proteins, Signal Transducing - genetics; Adult; Age of Onset; Biological and medical sciences; Diseases of striated muscles. Neuromuscular diseases; Dynamin II - genetics; Female; Humans; Male; Medical sciences; Middle Aged; Muscle, Skeletal - metabolism; Mutation - genetics; Myopathies, Structural, Congenital - genetics; Neurology; Nuclear Proteins - genetics; Tumor Suppressor Proteins - genetics; centronuclear myopathy; Striated muscle disease; Nervous system diseases; amphiphysin 2; BIN1; Myotubular myopathy; T-tubule; Mutation; Congenital disease; DNM2
• ISSN: 0006-8950; 1460-2156
• DOI: 10.1093/brain/awu272

Centronuclear myopathies are congenital muscle disorders characterized by type I myofibre predominance and an increased number of muscle fibres with nuclear centralization. The severe neonatal X-linked form is due to mutations in MTM1, autosomal recessive centronuclear myopathy with neonatal or childhood onset results from mutations in BIN1 (amphiphysin 2), and dominant cases were previously associated to mutations in DNM2 (dynamin 2). Our aim was to determine the genetic basis and physiopathology of patients with mild dominant centronuclear myopathy without mutations in DNM2. We hence established and characterized a homogeneous cohort of nine patients from five families with a progressive adult-onset centronuclear myopathy without facial weakness, including three sporadic cases and two families with dominant disease inheritance. All patients had similar histological and ultrastructural features involving type I fibre predominance and hypotrophy, as well as prominent nuclear centralization and clustering. We identified heterozygous BIN1 mutations in all patients and the molecular diagnosis was complemented by functional analyses. Two mutations in the N-terminal amphipathic helix strongly decreased the membrane-deforming properties of amphiphysin 2 and three stop-loss mutations resulted in a stable protein containing 52 supernumerary amino acids. Immunolabelling experiments revealed abnormal central accumulation of dynamin 2, caveolin-3, and the autophagic marker p62, and general membrane alterations of the triad, the sarcolemma, and the basal lamina as potential pathological mechanisms. In conclusion, we identified BIN1 as the second gene for dominant centronuclear myopathy. Our data provide the evidence that specific BIN1 mutations can cause either recessive or dominant centronuclear myopathy and that both disorders involve different pathomechanisms.